Why the study?
Does UP269-6 inhibit the pressor action of exogenous angiotensin I compared to enalapril or placebo in healthy normotensive male volunteers?
Does UP269-6 inhibit the pressor action of exogenous angiotensin I compared to enalapril or placebo in healthy normotensive male volunteers?
UP269-6 is a potent, orally active angiotensin II receptor antagonist that effectively blocks the angiotensin I pressor response in healthy volunteers.
Answers are grounded in this paper and cite their sources.
Supports dose selection for UP269-6 trials; extends human pharmacodynamic evidence for this novel ARB versus enalapril.
We assessed the inhibitory effect of UP269-6, a new orally active angiotensin II (ANG II) receptor antagonist, on the pressor action of exogenous ANG I in healthy male volunteers maintained on an unrestricted sodium intake and compared it with that of enalapril. Seven different single doses of UP269-6 ranging from 5 to 180 mg, 20 mg enalapril, or placebo were administered to 16 subjects in a double-blind fashion. The order of placebo and enalapril was randomized, and UP269-6 was given in an ascending dose order. The peak systolic blood pressure (SBP) response to a test dose of ANG I was determined serially before and after oral drug administration by monitoring finger BP by a photoplethysmographic method. No drug-related side effect was observed. There was a dose-dependent inhibition of the SBP response to the ANG I challenge. Doses as low as 40 to 80 mg had blocking effects quite similar to that of enalapril 20 mg. Ten hours after the 20- and 40-mg doses of UP269-6, the SBP response was still attenuated when drug levels no longer were measurable in plasma. UP269-6 also produced a dose-related increase in active renin and ANG II levels at 24 h after drug intake. In these volunteers on unrestricted salt intake, no statistically significant effect on 24-h urinary aldosterone excretion was observed. Based on these preliminary data, the pharmacokinetic drug half-life (t 1/2) was estimated at 4.7 h and the EC50 was estimated at 41 ng/ml. UP269-6 appears to be a well-tolerated, potent, orally active, antagonist of ANG II receptors in men. Doses of 40-80 mg might block the ANG I pressor response as does enalapril 20 mg.
No takes yet. Share an insight, caveat, or question.
Inglessis et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: